BridgeBio Pharma (BBIO) Current Leases (2020 - 2026)

BridgeBio Pharma (BBIO) has 7 years of Current Leases data on file, last reported at $4.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 14.78% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $4.4 million (down 14.78% YoY), and the FY2025 full-year result was $6.2 million, up 37.42% from the prior year.
• Current Leases retreated to $4.4 million in Q1 2026, from $6.2 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $6.2 million in Q4 2025 to a low of $3.7 million in Q1 2023.
• A 5-year average of $4.5 million and a median of $4.4 million in 2026 frame the typical range for Current Leases.
• Across the five-year window, Current Leases retreated 25.58% in 2022 and surged 37.42% in 2025, its largest moves.
• Tracing BBIO's Current Leases over 5 years: stood at $3.7 million in 2022, then advanced by 12.33% to $4.1 million in 2023, then increased by 9.16% to $4.5 million in 2024, then soared by 37.42% to $6.2 million in 2025, then retreated by 28.31% to $4.4 million in 2026.
• Business Quant data shows BBIO's Current Leases at $4.4 million in Q1 2026, $6.2 million in Q4 2025, and $5.3 million in Q3 2025.